Evidence map›Paper›PMID 32574267›Full record

ArticleFrontiers in immunology2020

COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase.

Scott B Halstead, Ramesh Akkina

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Scott B HalsteadIndependent Researcher, Bethesda, MD, United States.
Ramesh AkkinaDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.

Funding

An Ultrasensitive In Vivo Latent HIV Viral Outgrowth Assay Using Humanized MiceR01AI120021 · NIAID · COLORADO STATE UNIVERSITY · PI AKKINA, RAMESH · 2015 to 2019
$3.4M
Modeling the molecular evolution of SIV to HIV using humanized miceR01AI123234 · NIAID · COLORADO STATE UNIVERSITY · PI AKKINA, RAMESH · 2016 to 2020
$2.4M
NIAID NIH HHS R01 AI120021NIAID NIH HHS R01 AI123234
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralBetacoronavirusCoronavirus InfectionsCOVID-19HumansImmunization, PassivePandemicsPneumonia, ViralSARS-CoV-2Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, Viralantibody protection for Covid-19antibody therapy for Covid-19convalescent plasma for Covid-19 therapygamma globulin for Covid-19 protectionhuman volunteer testing for Covid-19 protectionSARS Coronavirus 2 and Covid-19 immunitySARS-CoV-2 immunityvaccine and therapeutics testing for Covid-19

Identifiers

PMID32574267
PMCPMC7272599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.